Table 2.

Response to treatment with cladribine in advanced systemic mastocytosis

Parameter	Result
Number of cladribine cycles (median, range)	6 (1–7)
Median dose of cladribine per cycle (mg)	45 (35–60)
Response to cladribine (ORR;%)	67
Clinical improvement	3
Partial response	3
Stable disease	1
Disease progression	2
Median duration of response (years); (median, range)	1.45 (0.2–11.2)
Outcome
Death (n;%) due to	5 (56)
Transplant complications	1
Unknown (probably neurological infection)	1
Transformation into acute myeloid leukemia	1
Mastocytosis resistant to therapy	2
Alive (n;%)	4 (44)
OS at 1 year (%)	64
OS at 3 years (%)	38

ORR overall response rate, OS overall survival